Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Addition of an EGFR/TGFβ inhibitor with pembrolizumab in head and neck cancer

Emrullah Yilmaz, MD, PhD, Cleveland Clinic, Cleveland, OH, describes the rationale behind the addition of BCA101, a bifunctional EGFR/TGFβ inhibitor, with pembrolizumab, a PD-1 antibody, for patients with recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) in a dose expansion trial (NCT04429542). EGFR is an established target, where existing therapies such as cetuximab target EGFR in head and neck cancer. Inhibition of TGFβ additionally has immunomodulatory effects. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.